NASDAQ$MDXG
Mimedx Group Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
MiMedx's first quarter performance in 2021 reflected advancements in clinical programs and core business growth.
MiMedx Group, Inc. reported net sales of $60.0 million for Q1 2021, a slight decrease compared to $61.7 million in the prior year. The company is progressing with its late-stage clinical programs and expanding its field personnel.
- Completed final clinical visits in Phase 3 studies for Plantar Fasciitis and Achilles Tendonitis.
- Announced completion of clinical effectiveness endpoint visits in a Phase 2B study for Knee Osteoarthritis.
- Appointed Dirk Stevens as Senior Vice President, Quality Assurance and Regulatory Affairs.
- Received FDA acceptance for the IND of AmnioFix® Injectable in Chronic Cutaneous Ulcers.
Headline financials
Revenue & EPS history
Mimedx · Revenue · Quarterly
$60M
Forward guidance
MiMedx anticipates that adjusted net sales for 2021 will align with the previous year due to the conclusion of the Enforcement Discretion period on May 31, 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+1.7%
Avg return
Earnings day
+2.9%
Avg return
5 days after
+7.2%
Avg return
30 days after
53%
34 / 64 earnings
Positive
+37.9%
Q1 2023
Best reaction
-23.3%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.1% | +6.2% | +8.2% | |
| Q4 2025 | -0.9% | -8.8% | -28.8% | |
| Q3 2025 | +2.6% | +7.0% | -4.3% | |
| Q1 2025 | -8.1% | -3.9% | -6.5% | |
| Q4 2024 | +1.6% | +1.1% | -5.9% | |
| Q3 2024 | +17.9% | +22.7% | +59.2% | |
| Q2 2024 | -12.0% | -17.7% | -9.9% | |
| Q1 2024 | +16.8% | +17.7% | +13.7% | |
| Q4 2023 | -2.9% | -1.7% | -8.3% | |
| Q3 2023 | +6.7% | +10.9% | +26.5% | |
| Q2 2023 | -4.6% | -4.2% | -8.1% | |
| Q1 2023 | +37.9% | +49.1% | +50.4% | |
| Q4 2022 | -11.4% | -6.4% | -29.0% | |
| Q3 2022 | -3.6% | +1.3% | +12.6% | |
| Q2 2022 | +8.2% | +15.5% | +2.3% | |
| Q1 2022 | +11.1% | -8.9% | -4.8% | |
| Q4 2021 | +1.4% | -1.6% | -4.0% | |
| Q3 2021 | +18.8% | +22.6% | +2.5% | |
| Q2 2021 | -2.5% | +1.4% | +23.4% | |
| Q1 2021 | -2.9% | -5.0% | +2.0% | |
| Q4 2020 | -15.3% | -13.4% | +13.8% | |
| Q3 2020 | +3.4% | -8.2% | -5.6% | |
| Q2 2020 | +2.3% | +4.2% | +14.4% | |
| Q2 2018 | +8.2% | +3.2% | +18.2% | |
| Q1 2020 | +8.2% | +3.2% | +18.2% | |
| Q4 2018 | +8.2% | +3.2% | +18.2% | |
| Q4 2019 | +8.2% | +3.2% | +18.2% | |
| Q2 2019 | +8.2% | +3.2% | +18.2% | |
| Q1 2018 | +8.2% | +3.2% | +18.2% | |
| Q1 2019 | +8.2% | +3.2% | +18.2% | |
| Q3 2019 | +8.2% | +3.2% | +18.2% | |
| Q4 2017 | -21.6% | -22.1% | -14.0% | |
| Q3 2018 | -1.3% | -8.6% | -7.0% | |
| Q3 2017 | +4.1% | +8.7% | -4.9% | |
| Q2 2017 | +0.7% | +2.1% | +5.9% | |
| Q1 2017 | +8.2% | +19.1% | +17.5% | |
| Q4 2016 | -3.9% | +3.4% | +9.8% | |
| Q3 2016 | +4.9% | +8.0% | +19.1% | |
| Q2 2016 | -0.9% | -1.7% | -5.6% | |
| Q1 2016 | -1.4% | — | — | |
| Q4 2015 | -0.4% | — | — | |
| Q3 2015 | -23.3% | — | — | |
| Q2 2015 | -13.5% | — | — | |
| Q1 2015 | +0.9% | — | — | |
| Q4 2014 | +8.7% | — | — | |
| Q3 2014 | +13.2% | — | — | |
| Q2 2014 | +5.5% | — | — | |
| Q1 2014 | -3.8% | — | — | |
| Q4 2013 | +2.2% | — | — | |
| Q3 2013 | -3.5% | — | — | |
| Q2 2013 | +0.8% | — | — | |
| Q1 2013 | -2.2% | — | — | |
| Q4 2012 | +8.5% | — | — | |
| Q3 2012 | +13.5% | — | — | |
| Q2 2012 | -4.8% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2011 | -4.2% | — | — | |
| Q2 2011 | -2.5% | — | — | |
| Q1 2011 | -3.7% | — | — | |
| Q4 2010 | +5.8% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | -4.8% | — | — | |
| Q1 2010 | +4.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro